Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis

Exclusion Criteria

• •1. Any condition that would render the patient or the caregiver unsuitable for the study, or place them at substantial risk of adverse outcome.
• •2. Unwillingness/inability of the patient to fulfill the study requirements.
• •3. Evidence of major depression or a score on the BDI-II \> or = 30 OR a score \< 30 on BDI-II but with endorsed suicidal ideation.
• •4. Hypothyroidism
• •5. B12 deficiency
• •6. Diabetes (Type 1 or 2).
• •7. Positive rapid plasma reagin.
• •8. Fasting triglyceride level\>2 times upper limit of normal value w/in 3 months of Study Visit 1.
• •9. History of malignancy of any organ system (other than localized squamous and basal cell carcinoma of the skin), treated or untreated, within the past 2 years.
• •10. Clinically significant renal disease or insufficiency.
• •11. Clinically significant hepatic disease or insufficiency.
• •12. Ethanol consumption greater than an equivalent of 2 oz/20 g/2 units of spirits per day OR 14 oz/140 g/14 units of spirits per week. One oz/10 g/1 unit of spirits = 6 oz/15 g/1 unit of wine = 12 oz/12 g/1 unit of beer.
• •13. History of current alcohol or substance abuse.
• •14. Known HIV infection.
• •15. History of head injury with loss of consciousness \> 30 minutes.
• •16. History of inflammatory bowel syndrome.
• •17. History of severe irritable bowel disease.
• •18. History of severe gastroesophageal reflux disease.
• •19. History of diverticular disease.
• •20. Use of any investigational compound within 30 days prior to screening.
• •21. Prior or current use of medium chain triglycerides for medical purposes.
• •22. Known allergies to dairy products or soy.
• •23. Use of anticholinergic medication within 30 days prior to Study Visit 1.
• •24. Use of acetylcholinesterase inhibitors within 30 days prior to Study Visit 1.
• •25. Use of memantine within 30 days prior to Study Visit 1.
• •26. Use of stimulants within 30 days prior to Study Visit 1
• •27. Use of modafinil, amantadine, and dalfampridine within 30 days prior to Study Visit 1, unless the dose has been stable for 90 days prior to Study Visit 1
• •28. Use of orlistat within 30 days prior to Study Visit 1.